ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

18 träffar

Bibliografisk träff 2023-12-20

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561

Bibliografisk träff 2021-05-10

Kinase Inhibitors as Underexplored Antiviral Agents.

García-Cárceles J, Caballero E, Gil C, Martínez A.

J Med Chem · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1021/acs.jmedchem.1c00302

Bibliografisk träff 2021-02-04

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.

Raghuvanshi R, Bharate SB.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.0c01467

Bibliografisk träff 2019-02-13

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.

Bestgen B, Kufareva I, Seetoh W, Abell C, Hartmann RW, Abagyan R, Le Borgne M, Filhol O, Cochet C, Lomberget T, Engel M.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.8b01765

Bibliografisk träff 2018-02-14

PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.

Jiang H, Zhu Y, Zhou Z, Xu J, Jin S, Xu K, Zhang H, Sun Q, Wang J, Xu J.

Cancer Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.1360

Bibliografisk träff 2015-08-01

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.4214

Bibliografisk träff 2011-10-30

Comprehensive analysis of kinase inhibitor selectivity.

Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.

Nat Biotechnol · journal article · DOI 10.1038/nbt.1990

Bibliografisk träff 2011-10-21

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.

Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2011.10.031

Bibliografisk träff 2010-09-01

Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR, Gray NS, Lee JD.

Cancer Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ccr.2010.08.008

Bibliografisk träff 2010-06-08

Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2010.06.030

Bibliografisk träff 2008-10-15

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA, Smith Y, Warmus JS, Tecle H.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.10.054

Bibliografisk träff 2008-10-07

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).

Warmus JS, Flamme C, Zhang LY, Barrett S, Bridges A, Chen H, Gowan R, Kaufman M, Sebolt-Leopold J, Leopold W, Merriman R, Ohren J, Pavlovsky A, Przybranowski S, Tecle H, Valik H, Whitehead C, Zhang E.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.10.015

Bibliografisk träff 2008-03-04

Pharmacophore identification of Raf-1 kinase inhibitors.

Zhu T, Jiao Y, Chen YD, Wang X, Li HF, Zhang LY, Lu T.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.02.068

Bibliografisk träff 2007-12-01

The selectivity of protein kinase inhibitors: a further update.

Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P.

Biochem J · research support, non-u.s. gov't; research-article; journal article · DOI 10.1042/bj20070797

Bibliografisk träff 2007-09-19

4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.

Spicer JA, Rewcastle GW, Kaufman MD, Black SL, Plummer MS, Denny WA, Quin J, Shahripour AB, Barrett SD, Whitehead CE, Milbank JB, Ohren JF, Gowan RC, Omer C, Camp HS, Esmaeil N, Moore K, Sebolt-Leopold JS, Pryzbranowski S, Merriman RL, Ortwine DF, Warmus JS, Flamme CM, Pavlovsky AG, Tecle H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm0704548

Bibliografisk träff 2006-12-01

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS.

Cancer Res · journal article · DOI 10.1158/0008-5472.can-06-2554

Bibliografisk träff 2003-09-01

Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.

Berger D, Dutia M, Powell D, Wu B, Wissner A, Boschelli DH, Floyd MB, Zhang N, Torres N, Levin J, Du X, Wojciechowicz D, Discafani C, Kohler C, Kim SC, Feldberg LR, Collins K, Mallon R.

Bioorg Med Chem Lett · journal article · DOI 10.1016/s0960-894x(03)00640-1

Bibliografisk träff 2000-10-01

Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Davies SP, Reddy H, Caivano M, Cohen P.

Biochem J · research support, non-u.s. gov't; research-article; journal article · DOI 10.1042/0264-6021:3510095